New guidelines for Aspirin dose
Reading File
Searching PubMed
aspirin dose guidelines cardiovascular prevention
Searching the Web
aspirin dosing guidelines 2024 2025 AHA ACC cardiovascular
Finding Sources
Searching PubMed
aspirin primary prevention guidelines 2024
Reading Web Page
https://www.jacc.org/doi/10.1016/j.jacc.2025.04.002
Reading File
Reading File
Searching the Web
aspirin 81mg vs 325mg current recommendation 2025 USPSTF secondary prevention
Here is a consolidated, up-to-date summary of aspirin dosing guidelines across all major clinical contexts:
Aspirin Dose: Current Guidelines (2025/2026)
The Standard Dose
Low-dose aspirin (75-100 mg/day, typically 81 mg in the US) is the universally recommended dose across all cardiovascular indications. The 325 mg dose offers no additional cardiovascular benefit and carries significantly higher bleeding risk. The CHARISMA trial confirmed 81 mg is optimal for safety and efficacy. - Fuster and Hurst's The Heart, 15th Ed.
1. Primary Prevention (No Prior Cardiovascular Event)
This is where the biggest guideline shift has occurred. The consensus has moved strongly away from routine aspirin use.
| Guideline | Recommendation |
|---|---|
| 2022 USPSTF | Individualize decision for ages 40-59 with ≥10% 10-year CVD risk (Grade C - small net benefit). Against initiating aspirin in adults ≥60 years (Grade D - bleeding risk outweighs benefit). |
| 2019 ACC/AHA Primary Prevention | Low-dose aspirin may be considered in select adults aged 40-70 at increased ASCVD risk without increased bleeding risk. Should NOT be routinely given to adults >70 years. |
| 2025 ADA Standards of Care (Diabetes) | Aspirin 75-162 mg/day may be considered in diabetic patients at increased CVD risk after individualized benefit-risk discussion (Level A). |
Bottom line: Do not start aspirin for primary prevention in most people over 60. Avoid in anyone with increased bleeding risk at any age.
2. Secondary Prevention (Established ASCVD)
Aspirin remains a clear Class I recommendation for secondary prevention across all major guidelines.
- Chronic Coronary Disease (2023 ACC/AHA): Low-dose aspirin 81 mg (75-100 mg) daily - Class I, Level A
- ACS / Post-MI (2025 ACC/AHA ACS Guideline): Early initiation of aspirin + a P2Y12 inhibitor (ticagrelor or prasugrel preferred, clopidogrel if others are unavailable/contraindicated) as Class I recommendations. Default DAPT duration is 1 year post-ACS without high bleeding risk.
- Stroke / TIA (AHA/ASA): Low-dose aspirin daily, or aspirin-dipyridamole combination, or clopidogrel alone (for aspirin-intolerant patients)
- Peripheral Artery Disease (ESC): Aspirin 75-160 mg once daily - Class I, Level A
3. DAPT Duration After ACS (2025 ACC/AHA)
| Scenario | Recommendation |
|---|---|
| Standard risk post-ACS | DAPT for 1 year (Class I) |
| High bleeding risk post-PCI | Switch to ticagrelor monotherapy at 1 month (Class I) |
| STEMI + fibrinolysis | Clopidogrel-based DAPT |
| NSTEMI + medical management only | Aspirin + ticagrelor (Class I) |
Note: The 2025 ACS guideline does not provide weight-based aspirin dosing recommendations, and there is no graded evidence distinguishing chewable vs. enteric-coated aspirin.
4. Special Situations
| Indication | Dose / Note |
|---|---|
| Preeclampsia prevention | Low-dose aspirin starting at 10-12 weeks gestation in women with hypertension or high risk (2025 ACC/AHA Hypertension Guideline) |
| Mechanical heart valves | Low-dose aspirin 75-100 mg + VKA (Class I, ACC/AHA and ESC) |
| Carotid stenosis (asymptomatic >50%) | Low-dose aspirin should be considered if bleeding risk is low (Class IIa) |
| CKD | Low-dose aspirin reduces cardiovascular events in CKD stages 3-5 based on recent meta-analysis (2025) |
| Kawasaki disease (acute phase) | High dose 30-50 mg/kg/day (anti-inflammatory) then switched to low-dose antiplatelet phase |
| VTE extended prevention | Aspirin is an option; 2025 meta-analysis confirms extended benefit (PMID 40382433) |
Key Takeaways
- 81 mg/day is the standard dose for all cardiovascular uses - higher doses only increase bleeding
- Primary prevention - avoid in most patients ≥60; individualize for ages 40-59 with ≥10% CVD risk
- Secondary prevention - aspirin remains essential; combine with a P2Y12 inhibitor after ACS for 1 year
- Bleeding risk always overrides - GI bleed risk, older age, and anticoagulant co-therapy are strong contraindications
- A 2026 Cochrane review found aspirin does not reduce colorectal cancer mortality and may increase cancer mortality in older adults - further undermining the case for primary prevention use
Is news of 75mg aspirin dose is isolated and 150mg is must
Searching PubMed
aspirin 75mg vs 150mg dose cardiovascular antiplatelet efficacy
Searching the Web
150mg aspirin better than 75mg evidence 2024 2025 myth fact
Finding Sources
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC11476763
Searching PubMed
aspirin low dose optimal 75 100 mg platelet inhibition
This is a very important clarification. Here is a direct, evidence-based answer:
Is 75 mg Aspirin Outdated and 150 mg Mandatory?
No. This claim is false for cardiovascular disease. Here is the breakdown by context:
For Cardiovascular Disease (Primary & Secondary Prevention)
75-100 mg is the gold standard. 150 mg is NOT recommended.
The evidence is clear and consistent:
- ADAPTABLE Trial (2021, 15,000+ patients with established ASCVD): Aspirin 81 mg was not inferior to 325 mg for preventing MI, stroke, or cardiovascular death - and had better adherence with less bleeding. There is no trial showing 150 mg outperforms 75-100 mg for cardiovascular outcomes.
- CHARISMA Trial: Confirmed that 81 mg is the optimal dose for cardiovascular prevention - more is not better, only more dangerous.
- ACC/AHA, ESC, WHO, USPSTF all recommend 75-100 mg/day. Not 150 mg. Not 325 mg.
- Higher doses above 100 mg increase GI bleeding risk without adding antiplatelet benefit, because platelet COX-1 is already maximally inhibited at doses as low as 30-50 mg daily.
The pharmacology explains why: aspirin irreversibly inhibits platelet thromboxane A2 production. This effect is complete at 75-81 mg. Giving 150 mg or 325 mg adds no further antiplatelet effect on platelets but does add more COX-1/COX-2 inhibition in the gastric mucosa - which is where the bleeding comes from.
The ONE Exception: Preeclampsia Prevention in Pregnancy
This is the only context where 150 mg has a real evidence base and is debated:
- The ASPRE Trial (2017) used 150 mg/night and showed a 62% reduction in preterm preeclampsia in high-risk women identified by first-trimester screening.
- The ESC and ISUOG guidelines for preeclampsia prevention now recommend 150 mg/day (starting 11-14 weeks gestation) for high-risk women.
- However, ACOG and US guidelines still recommend 81 mg, because the ASPRE screening algorithm (using uterine artery Doppler + placental growth factor + PAPP-A) is not widely used in the US, and no head-to-head 81 mg vs. 150 mg RCT in a US population has been completed.
- A 2024 RCT protocol (PMID: PMC11476763) is actively comparing 75 mg vs. 150 mg for preterm preeclampsia prevention - results are still pending.
Summary Table
| Context | Recommended Dose | Is 150 mg recommended? |
|---|---|---|
| Cardiovascular secondary prevention | 75-100 mg/day | No |
| Post-ACS / post-PCI (DAPT) | 75-100 mg/day | No |
| Primary prevention (select patients) | 75-100 mg/day | No |
| Stroke / TIA prevention | 75-100 mg/day | No |
| Preeclampsia prevention - European/high-risk | 150 mg/night (ESC) | Yes, in this context only |
| Preeclampsia prevention - US/ACOG | 81 mg/day | Not required |
Bottom Line
The claim that "75 mg is isolated and 150 mg is mandatory" appears to be a misapplication of the preeclampsia evidence to the general cardiovascular field. They are completely different clinical contexts.
For any cardiovascular indication, 75-100 mg remains the standard of care worldwide and there is no guideline body - not AHA, not ESC, not WHO - recommending 150 mg for cardiovascular prevention. Increasing the dose above 100 mg only increases harm.
This is a shared conversation. Sign in to Orris to start your own chat.